A new study found a correlation with an increase in emergency cardiovascular events in people under the age of 40 at the start of the Israeli COVID-19 vaccine program.
Published on Nature JournalUsing data from the Israeli National Emergency Medical Services from 2019 to 2021, researchers aged 16 to 39 across Israel “with potential factors such as COVID-19 infection and vaccination rates” Evaluated the year-old first aid (EMS) call.
They found a 25% increase in EMS calls between January 2021 and May 2021 compared to 2019 and 2020. Israel, which primarily uses Pfizer’s mRNA vaccine, launched the COVID-19 vaccine program in late December 2020.
“The number of weekly emergency calls was significantly associated with the first and second vaccine doses given to this age group, but not with the COVID-19 infection rate,” they said. Found. “Although no causal relationship has been established, findings raise concerns about undetected severe cardiovascular side effects induced by the vaccine and highlight the already established causal relationship between the vaccine and myocarditis. This is a frequent cause of unexpected cardiac arrest in young individuals. “
They incorporated EMS and related data in assessing vaccine side effects and COVID-19 outcomes to identify potential new health trends, such as increased EMS calls, and “potential root causes. We recommend that you investigate quickly.
A recent study by Swedish researchers on populations in Finland, Denmark, Sweden, and Norway showed that people who received the COVID-19 vaccine needed more hospital treatment than those who did not. It was suggested that there was a lot of heart inflammation.
“These extra cases in men aged 16 to 24 years are five times more risky after Comirnaty and 15 times more risky after Spikevax than unvaccinated,” said a professor at the Swedish Medical Products Agency. The study told the Epoch Times last week, Dr. Rickard Ljung, a doctor and doctor. Spikevax is the name of Moderna’s COVID-19 vaccine and Comirnaty is Pfizer’s vaccine.
His team found that the incidence of myocarditis or pericarditis was higher than the level of the unvaccinated cohort, or 38 per 100,000 after the second dose of mRNA vaccine. ..
In a study published on April 28, an Israeli research team said, “The benefits of COVID-19 vaccination are clear, especially in the elderly and developing serious and potentially life-threatening illnesses such as immunodeficiency. It is clear for those who are at high risk of doing so. ” Individual. However, they said, “It is important to better understand the potential risks in order to minimize the potential harm.”
How many Israeli scientists have included “self-reporting bias” when individuals report symptoms through reporting systems such as the Vaccine Adverse Event Reporting System (VAERS) operated by the U.S. Federal Government when conducting investigations. I focused on the potential flaws. Overreporting of vaccine-related symptoms. “
“Even studies from Israel based on more aggressive data collection state that some of the potentially relevant cases were not fully investigated,” they said.
The second problem researchers have encountered is how the symptoms of myocarditis, a type of heart inflammation, manifest.
“Myocarditis is a particularly insidious disease with multiple reported symptoms,” they said. “There is a vast body of literature highlighting asymptomatic cases of myocarditis, which are often underdiagnosed.”
On the other hand, “myocardial injury and myocarditis [are] It is widespread not only in vaccinated patients, but also in patients with COVID-19 infections. “
“Because the deployment of the COVID-19 vaccine is often done with COVID-19 infection in the background community, is the increased incidence of myocarditis and related cardiovascular conditions due to COVID-19 infection? It can be difficult to determine if it is due to a vaccine. “
The US Centers for Disease Control and Prevention and most health agencies around the world state that the benefits of the COVID-19 vaccine outweigh the potential risks. CDC on that website To tell Most patients who develop myocarditis or pericarditis and are treated should respond well to treatment.
Symptoms include chest pain, shortness of breath, heartbeat and fluttering.